Company Cyber Security Posture
NANA
NA Company Details
NA
NA
NA
NA
NA
NA
Scan still pending
NA
NA
NA Risk Score (AI oriented)Between 200 and 800
This score is AI-generated and less favored by cyber insurers, who prefer the TPRM score.
NA Global Score.png)
Company Scoring based on AI Models
| Model Name | Date | Description | Current Score Difference | Score |
|---|---|---|---|---|
| AVERAGE-Industry | 03-12-2025 | This score represents the average cybersecurity rating of companies already scanned within the same industry. It provides a benchmark to compare an individual company's security posture against its industry peers. | N/A | Between 200 and 800 |
Company Cyber Security News & History
| Entity | Type | Severity | Impact | Seen | Url ID | Details | View |
|---|
Company Subsidiaries
NA
Access Data Using Our API
Get company history
Rapid.png)
NA Cyber Security News
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to acquire Verve. The ...
Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push
Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push ...
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion
Eli Lilly agreed to acquire Verve Therapeutics for $1 billion upfront, adding a cardiovascular disease treatment to its portfolio. The purchase ...
Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics
Eli Lilly's $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine.
Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn
Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn.
Lilly to buy gene-editing partner Verve for up to $1.3 billion in cardiac care push
Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to boost its pipeline of ...
Eli Lilly strikes deal to buy Crispr gene-editing biotech Verve
World's biggest drugmaker clinches $1.3bn deal as it hunts for experimental treatments to boost its pipeline.
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.
Eli Lilly (NYSE:LLY) Eyes US$1.3 Billion Acquisition Of Verve Therapeutics
Eli Lilly (NYSE:LLY) recently saw its stock price rise by 6.63% over the last month, a movement potentially influenced by significant events ...
NA Similar Companies
CSL
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by ou
Talecris Plasma Resources
Talecris Plasma Resources was established in 2006 to ensure a reliable and safe supply of plasma for the production of premium protein therapies that help save and enhance lives worldwide. Today, we are a nationwide network of 69 plasma collection centers guided by our unwavering commitment to safet
ICON plc
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality
Biocon
Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthc
Avantor
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development an
Agilent Technologies
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product
Frequently Asked Questions
Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
NA CyberSecurity History Information
How many cyber incidents has NA faced?
Total Incidents: According to Rankiteo, NA has faced 0 incidents in the past.
What types of cybersecurity incidents have occurred at NA?
Incident Types: The types of cybersecurity incidents that have occurred include .
Additional Questions
What Do We Measure?
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
These are some of the factors we use to calculate the overall score:
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.
